Flulaval (Flulaval) Patient Information: Side Effects and Drug Images at RxList

Pill Identifier Search

May 27, 2012

Flulaval

Flu (Influenza) »

Flu (influenza, conventional, and H1N1) facts

Influenza, commonly called "the flu," is caused by viruses that infect the respiratory tract.
Influenza viruses are divided into three types, designated A, B, and C, with A types usually causing the most problems in humans.
Most people who get the conventional or seasonal flu recover completely in one to two weeks, but some people develop serious and potentially life-threatening medical complications, such as pneumonia.
Much of the illness and death caused by conventional or seasonal influenza can be prevented by annual influenza vaccination.
Influenza A undergoes frequent antigenic changes that require new vaccines to be developed and people to obtain a new vaccination every year. New vaccine technology is being developed.
In April 2009, a new flu virus termed novel H1N1 swine flu developed in Mexico, rapidly spread worldwide, and caused the WHO to de...

Read the Flu (Influenza) article »

« Previous
1
2
3
4
5
6
7
8
9
10
Next »

Flulaval

The Common Cold Slideshow Pictures

Natural Cold and Flu Remedies Slideshow Pictures

Take the Cold & Flu Quiz

font size

FLULAVAL
(Influenza Virus Vaccine)

DRUG DESCRIPTION

FLULAVAL, Influenza Virus Vaccine, for intramuscular injection, is a trivalent, split-virion, inactivated influenza virus vaccine prepared from virus propagated in the allantoic cavity of embryonated hens' eggs. Each of the influenza virus strains is produced and purified separately. The virus is inactivated with ultraviolet light treatment followed by formaldehyde treatment, purified by centrifugation, and disrupted with sodium deoxycholate.

FLULAVAL is a sterile, translucent to whitish opalescent suspension in a phosphate-buffered saline solution that may sediment slightly. The sediment resuspends upon shaking to form a homogeneous suspension. FLULAVAL has been standardized according to USPHS requirements for the 2011-2012 influenza season and is formulated to contain 45 mcg hemagglutinin (HA) per 0.5-mL dose in the recommended ratio of 15 mcg HA of each of the following 3 strains: A/California/7/2009 NYMC X-181 (H1N1), A/Victoria/210/2009 NYMC X-187 (H3N2) (an A/Perth/16/2009-like virus), and B/Brisbane/60/2008. Thimerosal, a mercury derivative, is added as a preservative. Each dose contains 25 mcg mercury. Each dose may also contain residual amounts of egg proteins ( ≤ 1 mcg ovalbumin), formaldehyde ( ≤ 25 mcg), and sodium deoxycholate ( ≤ 50 mcg). Antibiotics are not used in the manufacture of this vaccine.

The vial stopper does not contain latex.

Last reviewed on RxList: 1/10/2012
This monograph has been modified to include the generic and brand name in many instances.